‹ BackThe Newspaper EditionFront PageExit to modern site ›
Liberty Bell Report

Health & Medicine

A Weight-Loss Shot for Children as Young as 6? What Parents Should Know About the New Wegovy Trial

A major study in the New England Journal of Medicine found semaglutide cut BMI sharply in children ages 6 to 11 with obesity. No GLP-1 drug is approved for kids that young, and the hardest questions are about the long run.

By REBECCA HARTMANStaff Correspondent · WASHINGTON · Nov 18, 7:00 PM · 3 min. read

Illustration: Photorealistic warm cinematic scene of a family kitchen table set for an evening meal in an American home, a bowl of fresh vegetables and fruit, glasses of water, a child's lunchbox and a small soccer ball on a chair, and on…

Illustration · Liberty Bell Report

A new study is forcing parents and pediatricians to confront a question that would have sounded unthinkable a decade ago: should a 6-year-old take a weekly weight-loss injection?

The answer from researchers is not yes or no, but it is now backed by data. The STEP Young trial, a phase 3, double-blind, placebo-controlled study of semaglutide, the drug sold as Wegovy, was published in the New England Journal of Medicine on Nov. 16. It tested the medicine in children ages 6 to under 12 with obesity, a group with few medical treatment options.

What the study found

The trial randomized 167 children, 112 to semaglutide and 55 to placebo, and both groups received counseling on healthy eating and activity, Becker's Hospital Review reported. At 68 weeks, children on semaglutide saw their body mass index fall by an average of 13.5%, while BMI rose 2.7% among children on placebo, according to Contemporary Pediatrics. By week 104, the published results show BMI down 9.4% in the semaglutide group and up 8.4% in the placebo group.

Healio reported that 79% of the children on semaglutide moved down at least one BMI category by 68 weeks, compared with 23% of those on placebo. For a child with severe obesity, that can mean lower blood pressure, better blood sugar and fewer of the joint and breathing problems that come with excess weight.

The side effects

The drug was not without cost. Adverse events were common in both groups, reported in 96% of children on semaglutide and 93% on placebo, and stomach-related problems were the most frequent and occurred more often with the drug, the study authors reported. Gastrointestinal side effects led one child on semaglutide to stop treatment. Parents who have watched adults struggle with nausea and vomiting on these drugs will understand why that matters for a second-grader.

Not approved for young children

It is important for families to know where things stand. No GLP-1 drug is yet authorized to treat obesity in children under 12, U.S. News & World Report noted. Wegovy is approved for teenagers 12 and older. A positive trial is one step toward a possible approval, not the same thing as one.

ABC News, reporting on the results, asked the question many parents are asking: even if the drugs work in children as young as 6, should kids be using them? Pediatric specialists will weigh the clear short-term benefit against what nobody yet knows: what years or decades on these medicines mean for a growing body, for puberty and for a child's relationship with food. Studies in adults have found that many people regain weight after stopping these drugs, and families should assume the same may be true for children.

What parents can do now

Childhood obesity is a real and serious health problem, and parents who are struggling with it should never feel ashamed to ask for help. A pediatrician is the right first call. The basics still matter most, and they are things families control: regular family meals at the table, more water and fewer sugary drinks, time outdoors, consistent bedtimes, and limits on screens that crowd out play.

Parents should also feel free to ask hard questions before any prescription. What happens if my child stops the drug? How will you monitor growth? What does it cost, and will insurance cover it? A good doctor will welcome those questions.

There is a deeper point, too. Scripture calls the body a temple, and caring for a child's health is part of a parent's calling. That care can include medicine when it is truly needed. But no injection replaces a family that eats together, plays together and prays together. The goal is a healthy child who grows into a healthy adult, not simply a smaller number on a chart.

What comes next

Any approval for children this young would require Novo Nordisk, which makes Wegovy, to seek it, and the Food and Drug Administration to weigh the long-term safety questions. For now, the study gives doctors a powerful new piece of evidence, and gives families a reason for both hope and caution. Children are not small adults, and decisions about their bodies belong first to their parents, guided by careful medical advice.

Sources

  1. ABC News: Study shows GLP-1s may work in children as young as 6. Should kids be using them? (link)
  2. New England Journal of Medicine: Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age (link)
  3. Healio: Wegovy leads to 'substantial' BMI decrease for children aged 6 to 11 years with obesity (link)
  4. Becker's Hospital Review: 1st big GLP-1 trial in kids under 12 delivers double-digit BMI drop: 6 notes (link)
  5. Contemporary Pediatrics: Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesity (link)
  6. U.S. News & World Report: GLP-1s for Kids Under 12: Safety, Qualifications & What Parents Must Know (link)

— 30 —

Read this story on the full website, with comments »

Also in Today’s Edition

Previous pageHealth & MedicineTurn the pageA New Daily Pill for Women Whose Breast Cancer Outsmarts…